| Name | Fatostatin |
| Description | Fatostatin is a specific inhibitor of SREBP activation, it impairs the activation of SREBP-1 and SREBP-2. Fatostatin binds to SCAP (SREBP cleavage-activating protein), and inhibits the ER-Golgi translocation of SREBPs. |
| In vitro | Fatostatin directly binds SCAP and blocks its ER-to-Golgi transport with IC50 of 2.5 and 10 μM in mammalian cells[1]. Fatostatin (0.1-1 μM; 3 days) inhibits the androgen-independent prostate cancer cell proliferation (IC50=0.1 μM) in an independent of the known IGF1-signaling pathway. Fatostatin inhibits insulin-induced adipogenesis of 3T3-L1 cells[2]. |
| In vivo | Fatostatin (30 mg/kg; i.p. injection; daily for 28 days) reduces adiposity, ameliorated fatty liver by reducing triglyceride (TG) storage, and lowered hyperglycemia in ob/ob mice[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (6.79 mM), Sonication is recommended.
DMSO : 50.5 mg/mL (171.53 mM), Sonication is recommended.
H2O : Insoluble
Ethanol : 70 mg/mL (237.76 mM), Sonication is recommended.
|
| Keywords | SREBP-mediated | SREBP | prostate | ob/ob | mice | insulin-induced | Inhibitor | inhibit | human | Golgi | gene | FattyAcidSynthase | Fatty Acid Synthase (FASN) | Fatty Acid Synthase | Fatostatin | expression | cancer | adipogenesis | 125B11 |
| Inhibitors Related | 2-Octanone | Dehydrocholate sodium | Betulin | Bakuchiol | Maltitol | Coenzyme A | Benzil | Orlistat | trans-Chalcone | L-Carnitine | Cetilistat | Fenipentol |
| Related Compound Libraries | Bioactive Compound Library | Anti-Obesity Compound Library | Anti-Cancer Metabolism Compound Library | Multi-Target Compound Library | Inhibitor Library | NO PAINS Compound Library | Metabolism Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
